• Jan Prochazka, Ales Hejcl, and Lidmila Prochazkova.
• Central ICU and Neurosurgical Pain Relief Service, Masaryk Hospital, Usti nad Labem, Czech Republic. jan.prochazka@mnul.cz
• Pain Med. 2011 Sep 1;12(9):1309-15.

BackgroundThe antinociceptive effect of intrathecal midazolam is based on its affecting spinal gamma-amino butyric acid receptors.ObjectiveTo evaluate pain relief in patients with chronic low back pain and failed back surgery syndrome after a single-shot intrathecal administration of midazolam.DesignA prospective, open-label study.Outcome MeasuresThe analgesic effect was determined using a patient questionnaire during subsequent visits to the pain therapy service. We classified at least a 50% pain reduction with improved quality of life and improved functional condition as a positive outcome.ResultsBetween 1995 and 2010, we performed 500 administrations: 227 administrations in 57 male patients and 273 administrations in 69 female patients. We performed 81 administrations for chronic low back pain and 419 administrations for failed back surgery syndrome. The average age of our patients was 50 years (range 28 to 86). The dose administered ranged from 2 to 5 mg of midazolam. The analgesic effect lasted 9.7 weeks on average, ranging from 1 week to 3 years; the most common reported duration was between 4 and 12 weeks (3 months). In 65% of patients, we achieved pain relief lasting 4 weeks or longer; in 13%, the administration provided no analgesic effect at all. The incidence of side effects (drowsiness, nausea, headache, or transient worsening of complaints) was rather low.ConclusionIntrathecal midazolam is a useful supplement to standard analgesic therapy with opioids, non-opioids, or spinal steroids.Wiley Periodicals, Inc.

28 keywords...

hide…